Back to News
Market Impact: 0.32
Ardelyx Targets $500M Revenue This Year, Profitability by 2027
Source: marketbeat.com
Corporate Guidance & OutlookHealthcare & BiotechCompany FundamentalsInvestor Sentiment & Positioning
Ardelyx expects nearly $500 million in 2026 revenue and projects profitability in 2027, driven by continued growth of IBS-C drug IBSRELA and hyperphosphatemia treatment XPHOZAH. The outlook signals meaningful commercial expansion for its two key products, although profitability remains more than a year away.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
ARDX0.62
More News
- Glanbia shares tumble 6% after Morgan Stanley cuts rating to underweight
- The latest twist in the saga between UBS and Swiss regulators involves bank's New York business
- Morgan Stanley downgrades Ebara stock rating on valuation concerns
- AI debt concerns grow as ING reportedly seeks buyers for $500 million of data center loans
- AI’s Grip on Financial Markets Was Never Clearer on the Way Down
- Tech stock rout, driven by US AI fears, continues in Asian trading